Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 Gene Therapy

Key Facts

1Phase 1/2 trial data for OPGx-BEST1 showed clinically meaningful visual function improvement in all five low-dose participants.

2The company aligned with the FDA on potential Phase 3 endpoints with dosing expected to begin in 2027.

3The company expects its cash runway to extend into 2029, supporting multiple clinical inflection points.

In a move reflecting the ongoing progress within the specialized gene therapy sector, Opus Genetics has announced promising results from its clinical trials. Phase 1/2 trial data for OPGx-BEST1 showed clinically meaningful visual function improvement in all five low-dose participants. According to reports, the company has aligned with the FDA on potential Phase 3 endpoints, with dosing expected to commence in 2027.

These developments come as biotech firms prioritize financial stability to support long-term research cycles. The company expects its current cash runway to extend into 2029, providing sufficient capital to reach multiple clinical inflection points. This liquidity is a critical factor in ensuring the continued development of the company's pipeline for inherited retinal diseases.

Regarding market performance, IRD stood at $4.34 (close September 08, 2026), having traded between a day high of $4.62 and a low of $4.31. With no immediate sector-specific catalysts in the upcoming economic calendar, investors will focus on the sustainability of this clinical momentum and its impact on the stock's current support levels.